Covid 19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

5 minutes ago
Coronavirus

ITeos nabs $125M as they prep Keytru­da com­bi­na­tion tri­al — if Covid-19 will let them

34 minutes ago
R&D
Venture

Dai­ichi Sankyo sinks $200M in­to new gene ther­a­py tech from Ul­tragenyx

2 hours ago
Cell/Gene Tx
Deals

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

2 hours ago
Coronavirus
Regulatory

Mo­tion de­nied: Gilead still on the hook for $1.5B in dam­ages over CAR-T patent dis­pute with Bris­tol My­ers Squibb

2 hours ago
Cell/Gene Tx
People

A quiver of ar­rows for im­mune dis­or­ders: Pan­dion scores $80M in fresh fund­ing

3 hours ago
Startups
Venture

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

23 hours ago
Coronavirus
R&D

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

23 hours ago
Protocols

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

23 hours ago
Regulatory

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

Yesterday
R&D

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

Yesterday
R&D
Venture

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

Yesterday
China
Coronavirus

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

Yesterday
Venture

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

Yesterday
Coronavirus

Eli Lil­ly antes up $60M gam­ble on a dis­cov­ery deal with GSK-backed biotech

Yesterday
Deals

Un­fazed by dis­rup­tions, Cowen's in­vest­ment arm backs AM-Phar­ma's $176M piv­otal plan around lethal con­di­tion

Yesterday
Venture

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Yesterday
R&D

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative adap­tions

Yesterday
Coronavirus
R&D

As­traZeneca ex­pands deal with Imag­inAb; Ovid posts promis­ing da­ta on Take­da-part­nered seizure drug

Yesterday
Protocols

David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio Base­Camp

Yesterday
R&D
Startups

New­ly-pub­lic Im­muno­vant an­nounces first proof-of-con­cept suc­cess

2 days ago
R&D

Lund­beck adds a Parkin­son's flop to its list of set­backs, writ­ing off a $1.1 bil­lion deal on mid-stage fail­ure

2 days ago
R&D

Ax­some re­ports late-stage de­pres­sion tri­al de­feat, shares wilt

2 days ago
R&D

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of piv­otal da­ta

2 days ago
Coronavirus
1234 Next page Last page